Mink Therapeutics
| Mink Therapeutics
Company
Deck Type
Sector
Industry
Deck date
November 2022
Slide
27 of 92
Related slides by other companies
Immix Biopharma
Investor Presentation
November 2023
potential to disrupt the oncology and immunology categories | Immix Biopharma
Kymera
Investor Day
December 2021
degrader first in class opportunity to address driven pathology across diverse indications first degrader against an undrugged target in the clinic profound single agent activity in liquid tumor and promising activity with anti in liquid and solid tumors clinical development strategy includes direct registrational path in pathway activated heme malignancies opportunity for expansion into solid tumors in combination with immune inhibitors | Kymera
Recursion Pharmaceuticals
Investor Day
January 2023
clinical sustained signaling is a frequent driver event found across a wide variety of solid tumors of destruction complex due to inactivating mutations in leads to sustained signaling promoting cancer progression and survival mutant solid tumors are considered clinically aggressive and resistant to standard treatments disease overview cancers | Recursion Pharmaceuticals
Nuvalent
Investor Presentation
November 2023
for positive advanced and other solid tumors | Nuvalent
Other recent decks by Mink Therapeutics
See all presentations (2 decks)
IPO
October 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights